Supplementary Figure S4 from Immunoregulation and Clinical Implications of ANGPT2/TIE2+ M-MDSC Signature in Non–Small Cell Lung Cancer

Lauret Marie Joseph, Elodie; Laheurte, Caroline; Jary, Marine; Boullerot, Laura; Asgarov, Kamal; Gravelin, Eléonore; Bouard, Adeline; Rangan, Laurie; Dosset, Magalie; Borg, Christophe; Adotévi, Olivier

doi:10.1158/2326-6066.22543585.v1

Supplementary Figure S4 from Immunoregulation and Clinical Implications of ANGPT2/TIE2⁺ M-MDSC Signature in Non–Small Cell Lung Cancer

journal contribution

posted on 2023-04-04, 01:04 authored by Elodie Lauret Marie Joseph, Caroline Laheurte, Marine Jary, Laura Boullerot, Kamal Asgarov, Eléonore Gravelin, Adeline Bouard, Laurie Rangan, Magalie Dosset, Christophe Borg, Olivier Adotévi

Blood cytokines according to the level of ANGPT2/TIE2+ M-MDSCs.

History

ARTICLE ABSTRACT

Myeloid-derived suppressor cells (MDSC) promote immunosuppression and are a target in the field of immuno-oncology. Accumulation of MDSCs is associated with poor prognosis and resistance to immunotherapy for several cancers. Here, we describe an accumulation of a subset of circulating monocytic MDSCs (M-MDSC) overexpressing TIE2, the receptor for angiopoietin-2 (ANGPT2), in patients with non–small cell lung cancer (NSCLC). Greater numbers of circulating TIE2+ M-MDSCs were detected in patients with NSCLC compared with healthy subjects, and this accumulation correlated with ANGPT2 concentration in blood. The presence of an ANGPT2-rich environment was associated with impairment of preexisting T-cell responses against tumor-associated antigens (TAA) in patients with NSCLC. We demonstrated that ANGPT2 sensitizes TIE2+ M-MDSCs such that these cells suppress TAA-specific T cells. In patients with NSCLC, upregulation of the ANGPT2/TIE2+ M-MDSC signature in blood was associated with a poor prognosis. Our results identify the ANGPT2/TIE2+ M-MDSC axis as a participant in tumor immune evasion that should be taken into account in future cancer immunotherapy.